2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.068 Alexander Spira NACLC23 Abstract

PP01.068 Alexander Spira NACLC23 Abstract

Pdf Summary

A recent study examined the real-world treatment patterns of patients with advanced Non-Small Cell Lung Cancer (NSCLC) who had EGFR exon 20 insertion mutations and were treated with either amivantamab (AMI) or mobocertinib (MOBO) after platinum-based chemotherapy. AMI is a bispecific antibody targeting EGFR and MET, while MOBO is an EGFR tyrosine kinase inhibitor. The study aimed to provide insights into patient characteristics and treatment patterns in real-world practice, as previous evidence of the efficacy and tolerability of these drugs was limited to clinical trials.<br /><br />The study utilized data from various electronic health record registries and included patients who received AMI or MOBO treatment and had documentation of EGFR exon 20 insertion mutations and prior platinum-based chemotherapy. Time to next treatment (TTNT) and time to treatment discontinuation (TTD) were assessed as indicators of treatment success. A TTNT event was defined as the occurrence of the next line of therapy or death, while treatment discontinuation was confirmed by a clinical visit at least 150 days after the end of the regimen, death, or initiation of the next line of therapy.<br /><br />The results showed that out of the 68 included patients, 44 initiated AMI and 24 initiated MOBO. The median follow-up time was 5.5 months for AMI and 2.9 months for MOBO. The median TTNT was 9.2 months for AMI and 4.2 months for MOBO, with 44% of AMI patients and 62% of MOBO patients experiencing a TTNT event. The median TTD was 8.6 months for AMI and 2.3 months for MOBO, with 46% of AMI patients and 67% of MOBO patients experiencing a TTD event.<br /><br />The study concluded that real-world AMI patients had median TTNT and TTD consistent with the median progression-free survival (PFS) observed in the AMI registrational trial, while MOBO patients had shorter median TTNT and TTD than the median PFS in the MOBO registrational trial. This suggests the need for further evaluation of the effectiveness and tolerability of MOBO from the patient perspective. TTNT and TTD can serve as useful indicators for evaluating how clinical trial outcomes translate to real-world clinical practice.

Keywords

Non-Small Cell Lung Cancer

NSCLC

EGFR exon 20 insertion mutations

amivantamab

mobocertinib

platinum-based chemotherapy

bispecific antibody

EGFR tyrosine kinase inhibitor

time to next treatment

time to treatment discontinuation